So far, ACCANIS has developed two mRNA assets from its RNAVIENNATM platform. One of them is encoding for Interferon-alpha (IFN-a) for the treatment of actinic keratosis and non-melanoma skin cancer.
The second one expresses fibroblast growth factor 2 (FGF-2). Accanis’ FGF-2 mRNA will be used as a potent anti-aging/skin rejuvenation agent. Also, atrophic scars will be treated with the same molecule.